High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study

被引：0
|
作者：
Blauvelt, A. [1 ]
Gudjonsson, J. [2 ]
Matheson, R. [1 ]
Liu, R. [3 ]
Shi, L. [3 ]
Photowala, H. [3 ]
Ehst, B. [1 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI USA
[3] AbbVie Inc, N Chicago, IL USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
LB1703
引用
收藏
页码：B16 / B16
页数：1
相关论文
共 50 条
  • [31] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Lebwohl, M.
    Ghislain, P.
    Kerdel, F.
    Gu, Y.
    Valdes, J. M.
    Thompson, E. H.
    Lynde, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E25 - E25
  • [32] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Lebwohl, M.
    Ghislain, P-D
    Kerdel, F.
    Gu, Y.
    Valdes, J.
    Thompson, E. H.
    Lynde, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 115 - 116
  • [33] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Crowley, Jeffrey J.
    Langley, Richard G.
    Gordon, Kenneth B.
    Pinter, Andreas
    Ferris, Laura K.
    Rubant, Simone
    Photowala, Huzefa
    Xue, Zhenyi
    Wu, Tianshuang
    Zhan, Tianyu
    Beeck, Stefan
    Shah, Megha
    Warren, Richard B.
    DERMATOLOGY AND THERAPY, 2022, 12 (02) : 561 - 575
  • [34] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Cabaleiro, Teresa
    Solano-Lopez, Guillermo
    Marquez, Beatriz
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
  • [35] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Jeffrey J. Crowley
    Richard G. Langley
    Kenneth B. Gordon
    Andreas Pinter
    Laura K. Ferris
    Simone Rubant
    Huzefa Photowala
    Zhenyi Xue
    Tianshuang Wu
    Tianyu Zhan
    Stefan Beeck
    Megha Shah
    Richard B. Warren
    Dermatology and Therapy, 2022, 12 : 561 - 575
  • [36] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
  • [37] A prospective noninterventional study to evaluate the psychosocial impact of biological treatment outcomes in patients with moderate-to-severe plaque psoriasis in the UK: interim results
    Bewley, Anthony
    Shafi, Mehbub
    Gorecki, Patricia
    Andiappan, Manoharan
    Kleyn, C. Elise
    Hunter, Hamish J. A.
    Shams, Kave
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 224 - 225
  • [38] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [39] Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study
    Gottlieb, Alice B.
    Merola, Joseph F.
    Reich, Kristian
    Behrens, Frank
    Nash, Peter
    Bao, Weibin
    Pellet, Pascale
    Pricop, Luminita
    McInnes, Iain B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB92 - AB92
  • [40] Maintenance regimen of secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the OPTIMISE study
    Reich, Kristian
    Puig, Lluis
    Szepietowski, Jacek C.
    Paul, Carle
    Lacour, Jean Philippe
    Tsianakas, Athanasios
    Sieder, Christian
    Rissler, Michael
    Jagiello, Piotr
    Orsenigo, Roberto
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB90 - AB90
12345